Arena Pharmaceuticals, Inc. (ARNA): Price and Financial Metrics
Arena Pharmaceuticals, Inc. (ARNA)
Today's Latest Price: $42.00 USD
Updated Mar 31 8:00pm
Add ARNA to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
ARNA Stock Summary
- ARNA's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 8.03% of US stocks.
- Over the past twelve months, ARNA has reported earnings growth of -482.68%, putting it ahead of merely 3.15% of US stocks in our set.
- Revenue growth over the past 12 months for Arena Pharmaceuticals Inc comes in at 4,387.65%, a number that bests 99.68% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to Arena Pharmaceuticals Inc, a group of peers worth examining would be PRQR, CYAD, PULM, VYGR, and SMMT.
- Visit ARNA's SEC page to see the company's official filings. To visit the company's web site, go to www.arenapharm.com.
ARNA Stock Price Chart More Charts
ARNA Price/Volume Stats
| Current price | $42.00 | 52-week high | $64.48 |
| Prev. close | $42.12 | 52-week low | $32.95 |
| Day low | $41.03 | Volume | 869,000 |
| Day high | $43.39 | Avg. volume | 625,411 |
| 50-day MA | $45.87 | Dividend yield | N/A |
| 200-day MA | $50.19 | Market Cap | 2.11B |
Arena Pharmaceuticals, Inc. (ARNA) Company Bio
Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing drugs to address unmet medical needs. The company was founded in 1997 and is based in San Diego, California.
ARNA Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $42.00 | $632.29 | 1320% |
We started the process of determining a valid price forecast for Arena Pharmaceuticals Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Arena Pharmaceuticals Inc ranked in the 86th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 1326.67%. The most interesting components of our discounted cash flow analysis for Arena Pharmaceuticals Inc ended up being:
- The company's debt burden, as measured by earnings divided by interest payments, is 107.01; that's higher than 93.96% of US stocks in the Healthcare sector that have positive free cash flow.
- The business' balance sheet reveals debt to be 2% of the company's capital (with equity being the remaining amount). Approximately merely 8.06% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- ARNA's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 59.14% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 1292% |
| 1% | 1306% |
| 2% | 1320% |
| 3% | 1334% |
| 4% | 1347% |
| 5% | 1361% |
Want more companies with a valuation profile/forecast similar to that of Arena Pharmaceuticals Inc? See CRHM, STAA, INCY, PETQ, and INBP.
Top Stories View All
Best & Worst Performing Stock Industries for March 31, 2020
Best & Worst Performing Small Cap Stocks for March 31, 2020
Best & Worst Performing Mid Cap Stocks for March 31, 2020
Best & Worst Performing Large Cap Stocks for March 31, 2020
Best & Worst Performing Mega Cap Stocks for March 31, 2020
View All Top Stories
Loading social stream, please wait...